OBJECTIVE: To compare outcome between patients with and without super-response to cardiac resynchronization therapy-defibrillator (CRT-D). METHODS AND RESULTS: In this cohort study, 167 consecutive CRT-D candidates were included. Super-response to CRT-D was defined clinically [improvement of ≥1 New York Heart Association (NYHA) class or ≥50 m in six-minute walk distance (6MWD)] and echocardiographically [increase of left ventricular ejection fraction (LVEF) ≥1 category (LVEF <30 to 30-40 % or 30-40 to 41-51 %) or reduction of left ventricular end-diastolic diameter (LVEDD) ≥10 mm]. Clinical outcome (death, cardiac transplantation and appropriate shock therapy) was compared between super-responders (n = 32) and non-super-responders (n = 135). During follow-up (616 patient-years; median 3.3 years), all-cause mortality was significantly lower in super-responders compared to non-super-responders (log rank p < 0.05). At least one appropriate shock was noted in 22 % of super-responders and 39 % of non-super-responders (p = 0.069). Time to appropriate shock therapy was significantly longer in super-responders (log rank p < 0.05). Event-free survival from death or cardiac transplantation was comparable between the two groups. CONCLUSION: Super-response to CRT-D is associated with improved survival and lower risk of appropriate shock therapy compared to non-super-responders. Further information about the mechanisms of super-response and its long-term consequences are needed to foresee favorable outcome after implantation of CRT-D.
OBJECTIVE: To compare outcome between patients with and without super-response to cardiac resynchronization therapy-defibrillator (CRT-D). METHODS AND RESULTS: In this cohort study, 167 consecutive CRT-D candidates were included. Super-response to CRT-D was defined clinically [improvement of ≥1 New York Heart Association (NYHA) class or ≥50 m in six-minute walk distance (6MWD)] and echocardiographically [increase of left ventricular ejection fraction (LVEF) ≥1 category (LVEF <30 to 30-40 % or 30-40 to 41-51 %) or reduction of left ventricular end-diastolic diameter (LVEDD) ≥10 mm]. Clinical outcome (death, cardiac transplantation and appropriate shock therapy) was compared between super-responders (n = 32) and non-super-responders (n = 135). During follow-up (616 patient-years; median 3.3 years), all-cause mortality was significantly lower in super-responders compared to non-super-responders (log rank p < 0.05). At least one appropriate shock was noted in 22 % of super-responders and 39 % of non-super-responders (p = 0.069). Time to appropriate shock therapy was significantly longer in super-responders (log rank p < 0.05). Event-free survival from death or cardiac transplantation was comparable between the two groups. CONCLUSION: Super-response to CRT-D is associated with improved survival and lower risk of appropriate shock therapy compared to non-super-responders. Further information about the mechanisms of super-response and its long-term consequences are needed to foresee favorable outcome after implantation of CRT-D.
Authors: Claudia Ypenburg; Rutger J van Bommel; C Jan Willem Borleffs; Gabe B Bleeker; Eric Boersma; Martin J Schalij; Jeroen J Bax Journal: J Am Coll Cardiol Date: 2009-02-10 Impact factor: 24.094
Authors: Paul W X Foley; Shajil Chalil; Kayvan Khadjooi; Nick Irwin; Russell E A Smith; Francisco Leyva Journal: Eur J Heart Fail Date: 2010-11-04 Impact factor: 15.534
Authors: John Rickard; Dharam J Kumbhani; Zoran Popovic; David Verhaert; Mahesh Manne; Daniel Sraow; Bryan Baranowski; David O Martin; Bruce D Lindsay; Richard A Grimm; Bruce L Wilkoff; Patrick Tchou Journal: Heart Rhythm Date: 2010-04-08 Impact factor: 6.343
Authors: Steven M Markowitz; Jason M Lewen; Christopher J Wiggenhorn; William T Abraham; Kenneth M Stein; Sei Iwai; Bruce B Lerman Journal: J Cardiovasc Electrophysiol Date: 2008-10-30
Authors: Frederik H Verbrugge; Matthias Dupont; Philippe De Vusser; Maximo Rivero-Ayerza; Hugo Van Herendael; Jan Vercammen; Linda Jacobs; David Verhaert; Pieter Vandervoort; W H Wilson Tang; Wilfried Mullens Journal: Eur J Heart Fail Date: 2012-09-20 Impact factor: 15.534
Authors: W von Scheidt; C Zugck; M Pauschinger; R Hambrecht; O Bruder; A Hartmann; M Rauchhaus; R Zahn; J Brachmann; U Tebbe; T Neumann; R H Strasser; M Böhm; S Störk; M Hochadel; P Heidemann; J Senges Journal: Clin Res Cardiol Date: 2014-07-23 Impact factor: 5.460
Authors: Alexander P Benz; Mate Vamos; Julia W Erath; Peter Bogyi; Gabor Z Duray; Stefan H Hohnloser Journal: Clin Res Cardiol Date: 2018-05-24 Impact factor: 5.460
Authors: Martin Stockburger; Arthur J Moss; Helmut U Klein; Wojciech Zareba; Ilan Goldenberg; Yitschak Biton; Scott McNitt; Valentina Kutyifa Journal: Clin Res Cardiol Date: 2016-06-18 Impact factor: 5.460
Authors: Spyridon Liosis; Evgeny Lyan; Amr Abdin; Ben Brüggemann; Stefan A Lange; Julia Vogler; Christian H Heeger; Kivanc Yalin; Roland R Tilz; Charlotte Eitel Journal: Am J Case Rep Date: 2019-06-09